Username Password
S&P 500: 1,340.35 Change: -0.84%
mkittels
P&P Score: 2.73 | Points: -59.35 | Accuracy: 42.71 | Average Pick Score: 2.49   Annual Return: N/A  
Open
 
Closed
 
All
 
Commentary
BUY: BIOCRYST PHARMACEUTICALS INC. (BCRX) Rating: 3
Start Price: $10.94
Points: -64.70
Created: 10/26/2009
The 10/24 okay for using the antiviral drug for H1N1 should greatly benefit stockholders.

4 Comment(s):

Author mkittels     Date 2009-12-25 23:00:44
I've extended my holding period for BCRX, due to slower than anticipated good news. Their anti-viral has been used in intensive care units for patients not responsive to other therapies...but use lagged as H1N1 cases did not soar. I hold now awaiting FDA approval.
Author mkittels     Date 2010-10-21 01:41:28
BCRX's anti-viral treatment for flu still seems to me to be the best available...but I've held this too long now, with only a huge loss to show for my loyalty!
Author InvestmentMAGE     Date 2010-10-21 06:41:34
According to ValueEngine, BCRX 44.37% undervalued.
Recommend you hold for at least 6 more months.

Just my humble opinion.

MAGE
Author InvestmentMAGE     Date 2010-10-21 09:27:23
So, how long have you been a New World Investor?
Want to comment on this post? Sign up now. It's FREE!
Already registered? Log In.

register
Sponsored Links